Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)

NCT03189433 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Limited enrollment

Conditions

Drug Toxicity Psychotropic Agents Psychostimulants

Interventions

DRUG: Ryanodex (dantrolene sodium) for injectable suspension

Sponsor

Eagle Pharmaceuticals, Inc.